Results 51 to 60 of about 14,813,386 (261)
Current strategies to improve CAR-T cell persistence [PDF]
Chimeric antigen receptor T (CAR-T) cell therapy has transformed the field of immunology by redirecting T lymphocytes toward tumor antigens. Despite successes in attaining remission rates as high as 70%, the performance of CAR therapy is limited by the ...
Soren, Ghorai, Ashley , Pearson
core +1 more source
CAR T-cell therapy and critical care : A survival guide for medical emergency teams. [PDF]
, 2021 Chimeric antigen receptor (CAR) T‑cells are genetically engineered to give T‑cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B‑cell malignancies.
Que, Yok-Ai +6 more
core +2 more sources
FEBS Letters, EarlyView.CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens +8 more
wiley +1 more source
Evaluation of Toxicity Associated with CAR-T Cell Therapy and Nursing Interventions [PDF]
Objective: Chimeric antigen receptor (CAR)-T cell therapy is a new immunotherapy approach that has started to been used in recent years and is developing rapidly.
Gülbeyaz CAN +3 more
core +1 more source
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. [PDF]
, 2022 BACKGROUND Novel chimeric antigen receptor T-cells (CAR-T) target the B-cell maturation antigen (BCMA) expressed on multiple myeloma cells. Assays monitoring CAR-T cell expansion and treatment response are being implemented in clinical routine ...
Pabst, Thomas +11 more
core +2 more sources
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Journal of Translational MedicineBackground Chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating malignant diseases, yet its efficacy is often limited by challenges such as controllability and the lack of tumor-specific antigens. Adapter CAR (AdCAR) T cells
Nele Knelangen +5 more
doaj +1 more source
Engineered TAP1 and TAP2 Proteins to Block the CD7 and HLA-I Surface Expression on CAR-T Cells
, 2022 reservedChimeric antigen receptor (CAR) T-cells are a novel and powerful cancer treatment, particularly for hematologic malignancies like lymphomas or leukemias.
BRUNELLO, VALERIA
core
Nanosensors in clinical development of CAR-T cell immunotherapy
, 2022 DigitalImmunotherapy using CAR-T cells is a new technological paradigm for cancer treatment. To avoid severe side effects and tumor escape variants observed for conventional CAR-T cells approach, adaptor CAR technologies are under development, where ...
Nguyen-Le, Trang Anh +21 more
core +1 more source
Liver organoids: modelling complexity in homeostasis and disease
FEBS Letters, EarlyView.Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley +1 more source